G2 Insider-dtet

FDA Cracks Down on Improper Marketing of SARS-CoV-2 Antibody Tests

By Glenn S. Demby | Aug 4, 2020 | 2 min read

...

Subscribe to View

Start a Free Trial for immediate access to this article

Try For Free

Already a member? Log in here

Supreme Court May Take on Its First Health Care Data Breach Case

By Glenn S. Demby | Nov 6, 2017 | 1 min read

From - Diagnostic Testing & Emerging Technologies
In a case to watch, CareFirst BlueCross BlueShield will ask the U.S. Supreme Court to consider its first health care data breach case. CareFirst is arguing that the…

. . . read more

Don’t Crash & Burn: Why Cutting Your Quality Department’s Budget is not a Good Idea

By Glenn S. Demby | Oct 18, 2017 | 6 min read

By Jennifer Dawson, MHA, DLM (ASCP) bio
Do you think that you can improve your organization's bottom line by reducing the budget to your quality program and cutting its staff…

. . . read more

Survey Finds Expected Growth in Analytical Instrumentation Purchases

By Glenn S. Demby | Mar 28, 2016 | 1 min read

From - Diagnostic Testing & Emerging Technologies
A new survey reveals that laboratories are planning to increase equipment purchases this year, with analytical instrumentation reported…

. . . read more

Genetic Risk of Disease Results Don’t Change Health-Related Behaviors

By Glenn S. Demby | Mar 21, 2016 | 1 min read

From - Diagnostic Testing & Emerging Technologies
Communicating genetic risk of disease estimates does not impact individuals' health related behaviors, according to a review published March 15 in the…

. . . read more

New Breast Cancer Staging System Incorporates HER2 Status to Better Assess Prognosis

By Glenn S. Demby | Mar 21, 2016 | 1 min read

From - Diagnostic Testing & Emerging Technologies
A new breast cancer staging system adds HER2 (ERBB2-positive disease) status to a list of factors used to assess prognosis in women who undergo neoadjuvant (pre-surgical) therapy for…

. . . read more